A Phase 2 Multicenter Randomized Clinical Trial of CNTF for MacTel

A Phase 2 Multicenter Randomized Clinical Trial of Ciliary Neurotrophic Factor (CNTF) for Macular Telangiectasia Type 2 (MacTel)

This study is a phase 2, randomized, multi-center, single-masked study to evaluate the efficacy and safety of the NT-501 implants in participants with Mactel.

Inclusion Criteria:

• Participant must be offered sufficient opportunity to review and to understand the informed consent form, agree to the form's contents and sign the protocol's informed consent
• Participant must have at least one study eye with a positive diagnosis of MacTel Type 2
• Participant must have an IS/OS PR break in the study eye(s) and en face ellipsoid zone (area of IS/OS loss) as measured by SDOCT between 0.16 mm2 and 4.00 mm2
• If female, participant must be incapable of pregnancy
• If male, participant must agree to use an effective form of birth control during the study

Exclusion Criteria:

• Participant is unable to provide informed consent
• Participant is less than 21 years of age or greater than 80 years of age
• Participant is medically unable to comply with study procedures or follow-up visits
• Participant was a study subject in any other clinical trial of an intervention (drug or device) within the last 6 months
• Participant is pregnant or breastfeeding